TY - JOUR
T1 - Current Practices and Variations in the Use of FDG-PET and Bone Marrow Biopsy in Ewing Sarcoma Diagnosis
T2 - A Survey of Provider Recommendations
AU - Offenbacher, Rachel
AU - Epstein, Abigail
AU - Collier, Anderson B
AU - Lin, Juan
AU - Hosgood, H Dean
AU - Moerdler, Scott
N1 - Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2026/7/1
Y1 - 2026/7/1
N2 - INTRODUCTION: Ewing sarcoma (ES) is the second most common malignant bone and soft tissue tumor in children, adolescents, and young adults. Current consensus guidelines, consistent with Children's Oncology Group practice, support the universal use of full-body fluorodeoxyglucose positron emission tomography (FDG-PET) and recommend reserving bone marrow aspiration and biopsy for cases in which FDG-PET raises concern for marrow involvement, leaving final decisions to the treating physician. Although bone marrow metastasis is defined by morphologic evidence on biopsy rather than imaging alone, the extent to which these recommendations have influenced real-world practice is unknown.METHODS: A cross-sectional electronic survey of pediatric hematology-oncology and transplant attending physicians, advanced practice providers, and fellows was conducted to gather data on current practices regarding FDG-PET use and the decision to include bone marrow evaluation.RESULTS: A total of 392 providers completed this survey. Nearly all general oncologists (n=172) and solid tumor specialists (n=156) reported obtaining an FDG-PET for every patient presenting with ES, compared with all other hematology/oncology subspecialty providers (P=0.002). Providers who always obtain FDG-PET for newly diagnosed ES patients had a lower median year in practice (9 [3 to 17]) than those who do not (19 [8 to 21]) (P=0.018). However, more than half of providers reported obtaining a BM biopsy on every patient, independent of FDG-PET results. Based on a guideline-informed system, solid tumor oncologists demonstrated somewhat greater alignment with practice-based approaches compared with general oncologists (P=0.013).DISCUSSION: This study highlights the variation in the diagnostic evaluation of ES. Increased education and incorporation of practice-based guidelines into upfront clinical trials may help reduce practice variability.
AB - INTRODUCTION: Ewing sarcoma (ES) is the second most common malignant bone and soft tissue tumor in children, adolescents, and young adults. Current consensus guidelines, consistent with Children's Oncology Group practice, support the universal use of full-body fluorodeoxyglucose positron emission tomography (FDG-PET) and recommend reserving bone marrow aspiration and biopsy for cases in which FDG-PET raises concern for marrow involvement, leaving final decisions to the treating physician. Although bone marrow metastasis is defined by morphologic evidence on biopsy rather than imaging alone, the extent to which these recommendations have influenced real-world practice is unknown.METHODS: A cross-sectional electronic survey of pediatric hematology-oncology and transplant attending physicians, advanced practice providers, and fellows was conducted to gather data on current practices regarding FDG-PET use and the decision to include bone marrow evaluation.RESULTS: A total of 392 providers completed this survey. Nearly all general oncologists (n=172) and solid tumor specialists (n=156) reported obtaining an FDG-PET for every patient presenting with ES, compared with all other hematology/oncology subspecialty providers (P=0.002). Providers who always obtain FDG-PET for newly diagnosed ES patients had a lower median year in practice (9 [3 to 17]) than those who do not (19 [8 to 21]) (P=0.018). However, more than half of providers reported obtaining a BM biopsy on every patient, independent of FDG-PET results. Based on a guideline-informed system, solid tumor oncologists demonstrated somewhat greater alignment with practice-based approaches compared with general oncologists (P=0.013).DISCUSSION: This study highlights the variation in the diagnostic evaluation of ES. Increased education and incorporation of practice-based guidelines into upfront clinical trials may help reduce practice variability.
KW - Adolescent
KW - Biopsy
KW - Bone Marrow/pathology
KW - Bone Neoplasms/diagnostic imaging
KW - Child
KW - Cross-Sectional Studies
KW - Female
KW - Fluorodeoxyglucose F18
KW - Humans
KW - Male
KW - Positron-Emission Tomography/methods
KW - Practice Patterns, Physicians'
KW - Radiopharmaceuticals
KW - Sarcoma, Ewing/diagnostic imaging
KW - Surveys and Questionnaires
KW - Young Adult
KW - FDG-PET
KW - Ewing sarcoma
KW - metastatic disease
KW - real-world data
KW - bone marrow
UR - https://www.scopus.com/pages/publications/105043494408
U2 - 10.1097/MPH.0000000000003218
DO - 10.1097/MPH.0000000000003218
M3 - Article
C2 - 42274376
SN - 1077-4114
VL - 48
SP - e205-e208
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
IS - 5
ER -